Literature DB >> 9835904

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.

M S Ewer1, N Jaffe, H Ried, H A Zietz, R S Benjamin.   

Abstract

BACKGROUND: Doxorubicin cardiotoxicity remains a serious problem in children with malignancy. The present study was undertaken to determine if the administration of consecutive divided daily doses of doxorubicin would significantly reduce the likelihood of cardiotoxicity in children compared with a single dose administration regimen. PROCEDURE: One hundred thirteen children (60 boys and 53 girls) received doxorubicin either by single dose infusion or by a consecutive divided daily dose schedule. The divided dose patients received one third of the total cycle dose over 20 minutes for 3 consecutive days. Patients treated according to a single dose schedule received the cycle dose as a 20-minute infusion. The mean doxorubicin dose was 341 mg/m2. Patients were followed up for 4-180 months. There were 60 boys and 53 girls in the series.
RESULTS: Fifteen patients developed cardiacdysfunction, eight of whom died of progressive cardiac failure. There was no significant difference in the incidence of cardiac dysfunction between the divided and single dose infusion groups. More girls than boys developed cardiac dysfunction and more girls died of progressive cardiac failure; this difference was not statistically significant. The median time to the development of cardiac failure was 2 months.
CONCLUSIONS: The divided dose regimen did not alter the incidence of cardiotoxicity. Other schedules should therefore be investigated. Our data suggest that, at similar cumulative doses, girls are more likely to develop cardiac dysfunction than are boys. If the sex-related difference is proved in larger series of patients, it may be prudent to lower the recommended cumulative doses for girls.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835904     DOI: 10.1002/(sici)1096-911x(199812)31:6<512::aid-mpo8>3.0.co;2-4

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  14 in total

1.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

2.  Oxidative stress induced by low-dose doxorubicin promotes the invasiveness of osteosarcoma cell line U2OS in vitro.

Authors:  Seung Han Shin; Young Joon Choi; Hyewon Lee; Han-Soo Kim; Sung Wook Seo
Journal:  Tumour Biol       Date:  2015-08-23

3.  Dexrazoxane as a cardioprotectant in children receiving anthracyclines.

Authors:  Dana M Sepe; Jill P Ginsberg; Frank M Balis
Journal:  Oncologist       Date:  2010-11-04

4.  Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Bohumir Blazek; Jaroslav Michalek
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

5.  Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.

Authors:  Steven E Lipshultz; Tracie L Miller; Stuart R Lipsitz; Donna S Neuberg; Suzanne E Dahlberg; Steven D Colan; Lewis B Silverman; Jacqueline M Henkel; Vivian I Franco; Laura L Cushman; Barbara L Asselin; Luis A Clavell; Uma Athale; Bruno Michon; Caroline Laverdière; Marshall A Schorin; Eric Larsen; Naheed Usmani; Stephen E Sallan
Journal:  Pediatrics       Date:  2012-11-19       Impact factor: 7.124

Review 6.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.

Authors:  Michael S Ewer; Steven M Ewer
Journal:  Nat Rev Cardiol       Date:  2010-10       Impact factor: 32.419

Review 7.  Adriamycin-induced heart failure: mechanism and modulation.

Authors:  P K Singal; T Li; D Kumar; I Danelisen; N Iliskovic
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

Review 8.  Surviving childhood cancer: the impact on life.

Authors:  Robert E Goldsby; Denah R Taggart; Arthur R Ablin
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

9.  Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Jaroslav Michalek
Journal:  Support Care Cancer       Date:  2005-07-21       Impact factor: 3.603

10.  Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.

Authors:  Stuart Ibsen; Eran Zahavy; Wolf Wrasidlo; Tomoko Hayashi; John Norton; Yongxuan Su; Stephen Adams; Sadik Esener
Journal:  Photochem Photobiol       Date:  2013-03-06       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.